IDiyas

For the Inventor, By the Inventor

Wuppertal, Germany

Mark Meininghaus

USPTO Granted Patents = 11 

 

Average Co-Inventor Count = 13.1

ph-index = 3

Forward Citations = 33(Granted Patents)


Company Filing History:

goldMedal7 out of 378 
 
Bayer Pharma Aktiengesellschaft
 patents
silverMedal3 out of 721 
 
Bayer Intellectual Property Gmbh
 patents
bronzeMedal2 out of 12,157 
 
Bayer Aktiengesellschaft
 patents
4. 1 out of 192 
 
Bayer Schering Pharma Ag
 patents
where one patent can have more than one assignee

Years Active: 2010-2021

Loading Chart...
Loading Chart...
11 patents (USPTO):
1. 11149018 - Substituted N-arylethyl-2-aminoquinoline-4-carboxamides and use thereof (2021-10-19),
2. 11136296 - Substituted-arylethyl-2-arylquinoline-4-carboxamides and use thereof (2021-10-05),
3. 10479765 - Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents (2019-11-19),
4. 10435403 - Positive allosteric modulators of muscarinic M2 receptor (2019-10-08),
5. 10189788 - Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents (2019-01-29),
6. 10117864 - Substituted N-bicyclo-2-aryl-quinolin-4-carboxamides and use thereof (2018-11-06),
7. 8987248 - Substituted piperidines as Par-1 antagonists (2015-03-24),
8. 8324222 - Cyclically substituted furopyrimidine derivatives and use thereof (2012-12-04),
9. 8183246 - Acyclically substituted furopyrimidine derivatives and use thereof (2012-05-22),
10. 8119663 - Heteroaryl-substituted piperidines (2012-02-21),
11. 7776922 - Substituted [(phenylethanoyl)amino]benzamides (2010-08-17),

Title: Exploring the Innovations of Inventor Mark Meininghaus

Introduction:

Mark Meininghaus, a prolific inventor based in Wuppertal, Germany, has made significant contributions to the field of pharmaceuticals with his inventive spirit and dedication to scientific advancement.

Latest Patents:

Mark Meininghaus holds an impressive total of 11 patents, with his latest inventions focusing on substituted N-arylethyl-2-aminoquinoline-4-carboxamides and substituted-arylethyl-2-arylquinoline-4-carboxamides. These innovations offer promising solutions for the treatment and prevention of various diseases, particularly targeting fibrotic and inflammatory disorders.

Career Highlights:

Throughout his career, Mark Meininghaus has worked with renowned companies such as Bayer Pharma Aktiengesellschaft and Bayer Intellectual Property GmbH. His valuable contributions have helped these organizations drive forward in the pharmaceutical industry and develop cutting-edge medicinal products.

Collaborations:

In his inventive journey, Mark Meininghaus has collaborated closely with talented individuals such as Hartmut Beck and Raimund Kast. Together, they have combined their expertise to pioneer new solutions and advance scientific research in the field of medicine.

Conclusion:

Inventor Mark Meininghaus stands out as a visionary individual whose innovative mindset and collaborative efforts have led to groundbreaking patents in the pharmaceutical sector. His commitment to improving healthcare through inventive solutions continues to inspire and drive progress in the field of medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…